Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Core Insights - Johnson & Johnson is presenting 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology, focusing on advancements in neuropsychiatry, particularly in major depressive disorder (MDD) and treatment-resistant depression (TRD) [1][2] Group 1: Research Presentations - Key presentations include analyses of CAPLYTA (lumateperone) for remission in MDD, metabolic profiles of seltorexant versus quetiapine XR in MDD with insomnia, and effects of SPRAVATO (esketamine) on anhedonia in TRD [3][4] - Specific posters will cover the efficacy of lumateperone in various demographic and clinical subgroups, as well as treatment-emergent adverse events in MDD patients [3][4] Group 2: Company Commitment - Johnson & Johnson emphasizes its commitment to addressing unmet needs in depression, schizophrenia, and bipolar disorder, aiming for disease remission through innovative research and clinical findings [2] - The company is advancing its portfolio with a focus on novel mechanisms and AI-driven precision tools to redefine standards of care in neuropsychiatry [2] Group 3: Major Depressive Disorder (MDD) Insights - MDD affects approximately 332 million people globally, representing about 4% of the population, with around 22 million adults in the U.S. experiencing at least one major depressive episode in 2023 [6] - The disorder is complex and heterogeneous, with responses to treatment varying widely, highlighting the need for personalized approaches [6][7] - Approximately 60% of MDD patients experience insomnia symptoms, which significantly impact their quality of life and increase the risk of depressive relapse [7] Group 4: Treatment-Resistant Depression (TRD) Insights - About one-third of adults with MDD are classified as having TRD, defined as inadequate response to two or more oral antidepressants [8] - TRD poses a significant economic burden and affects patients' lives severely, with a high percentage not achieving remission even after multiple treatment attempts [8]